Charles J Kahi1, Krishna C Vemulapalli2, Cynthia S Johnson3, Douglas K Rex2. 1. Department of Medicine, Division of Gastroenterology and Hepatology, Indiana University School of Medicine, Indianapolis, Indiana, USA; Richard L. Roudebush Veterans Affairs Medical Center, Indianapolis, Indiana, USA. 2. Department of Medicine, Division of Gastroenterology and Hepatology, Indiana University School of Medicine, Indianapolis, Indiana, USA. 3. Department of Biostatistics, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Abstract
BACKGROUND: The adenoma detection rate (ADR) is a validated marker of colonoscopy quality. However, the optimal measurement method is unclear. OBJECTIVE: The aims of our study were to (1) define benchmarks for the number of adenomas per screening colonoscopy (APC) quality metric; (2) study the association between ADRs for screening, surveillance, and diagnostic indications; and (3) explore the association of the screening ADR with an overall ADR inclusive of all colonoscopy indications. DESIGN: Retrospective study. SETTING: University hospital and associated ambulatory surgery center endoscopy units. PATIENTS: Patients aged ≥50 years who underwent colonoscopy for screening, surveillance, or diagnostic indications by 20 endoscopists between January 1, 1999 and April 30, 2012. INTERVENTION: Colonoscopy. MAIN OUTCOME MEASUREMENTS: ADR, APC for screening, surveillance, and diagnostic indications. RESULTS: A total of 21,766 colonoscopies were included. The indication was screening in 7434 (34.2%), surveillance in 8338 (38.3%), and diagnostic in 5994 (27.5%). The screening ADRs and APCs were significantly correlated (R = 0.91; P < .0001). For men, an ADR of 25% corresponded to an APC of 0.46 (95% confidence interval [CI], 0.35-0.57); for women, an ADR of 15% corresponded to an APC of 0.20 (95% CI, 0.13-0.27). Overall, the ADR stratified by colonoscopy indication was highest for surveillance, followed by screening, then diagnostic. For men, a screening ADR of 25% corresponded to a surveillance ADR of 31.9% (95% CI, 24.8%-38.9%); for women, an ADR of 15% corresponded to a surveillance ADR of 24.3% (95% CI, 18.3%-30.5%). The corresponding diagnostic ADRs were 17.0% (95% CI, 12.4%-21.6%) and 15.4% (95% CI, 11.5%-19.3%), respectively. There was significant correlation between screening ADR and an overall ADR inclusive of all colonoscopy indications. LIMITATIONS: External generalizability, retrospective design. CONCLUSION: We propose minimum screening APC detection benchmarks of 0.50 for men and 0.20 for women. ADRs for screening, surveillance, and diagnostic colonoscopy are correlated and can be used to derive a simplified overall ADR inclusive of all colonoscopy indications. Published by Mosby, Inc.
BACKGROUND: The adenoma detection rate (ADR) is a validated marker of colonoscopy quality. However, the optimal measurement method is unclear. OBJECTIVE: The aims of our study were to (1) define benchmarks for the number of adenomas per screening colonoscopy (APC) quality metric; (2) study the association between ADRs for screening, surveillance, and diagnostic indications; and (3) explore the association of the screening ADR with an overall ADR inclusive of all colonoscopy indications. DESIGN: Retrospective study. SETTING: University hospital and associated ambulatory surgery center endoscopy units. PATIENTS: Patients aged ≥50 years who underwent colonoscopy for screening, surveillance, or diagnostic indications by 20 endoscopists between January 1, 1999 and April 30, 2012. INTERVENTION: Colonoscopy. MAIN OUTCOME MEASUREMENTS: ADR, APC for screening, surveillance, and diagnostic indications. RESULTS: A total of 21,766 colonoscopies were included. The indication was screening in 7434 (34.2%), surveillance in 8338 (38.3%), and diagnostic in 5994 (27.5%). The screening ADRs and APCs were significantly correlated (R = 0.91; P < .0001). For men, an ADR of 25% corresponded to an APC of 0.46 (95% confidence interval [CI], 0.35-0.57); for women, an ADR of 15% corresponded to an APC of 0.20 (95% CI, 0.13-0.27). Overall, the ADR stratified by colonoscopy indication was highest for surveillance, followed by screening, then diagnostic. For men, a screening ADR of 25% corresponded to a surveillance ADR of 31.9% (95% CI, 24.8%-38.9%); for women, an ADR of 15% corresponded to a surveillance ADR of 24.3% (95% CI, 18.3%-30.5%). The corresponding diagnostic ADRs were 17.0% (95% CI, 12.4%-21.6%) and 15.4% (95% CI, 11.5%-19.3%), respectively. There was significant correlation between screening ADR and an overall ADR inclusive of all colonoscopy indications. LIMITATIONS: External generalizability, retrospective design. CONCLUSION: We propose minimum screening APC detection benchmarks of 0.50 for men and 0.20 for women. ADRs for screening, surveillance, and diagnostic colonoscopy are correlated and can be used to derive a simplified overall ADR inclusive of all colonoscopy indications. Published by Mosby, Inc.
Authors: Grace Clarke Hillyer; Benjamin Lebwohl; Richard M Rosenberg; Alfred I Neugut; Randi Wolf; Corey H Basch; Jennie Mata; Edwin Hernandez; Douglas A Corley; Steven Shea; Charles E Basch Journal: Therap Adv Gastroenterol Date: 2014-11 Impact factor: 4.409
Authors: Timothy D Imler; Justin Morea; Charles Kahi; Eric A Sherer; Jon Cardwell; Cynthia S Johnson; Huiping Xu; Dennis Ahnen; Fadi Antaki; Christopher Ashley; Gyorgy Baffy; Ilseung Cho; Jason Dominitz; Jason Hou; Mark Korsten; Anil Nagar; Kittichai Promrat; Douglas Robertson; Sameer Saini; Amandeep Shergill; Walter Smalley; Thomas F Imperiale Journal: Am J Gastroenterol Date: 2015-03-10 Impact factor: 10.864
Authors: Maximilian Stephens; Luke F Hourigan; Mark Appleyard; George Ostapowicz; Mark Schoeman; Paul V Desmond; Jane M Andrews; Michael Bourke; David Hewitt; David A Margolin; Gerald J Holtmann Journal: World J Gastroenterol Date: 2015-04-28 Impact factor: 5.742
Authors: Gottumukkala S Raju; Phillip J Lum; Rebecca S Slack; Selvi Thirumurthi; Patrick M Lynch; Ethan Miller; Brian R Weston; Marta L Davila; Manoop S Bhutani; Mehnaz A Shafi; Robert S Bresalier; Alexander A Dekovich; Jeffrey H Lee; Sushovan Guha; Mala Pande; Boris Blechacz; Asif Rashid; Mark Routbort; Gladis Shuttlesworth; Lopa Mishra; John R Stroehlein; William A Ross Journal: Gastrointest Endosc Date: 2015-04-22 Impact factor: 9.427